Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6997516 | 0.89 | DUT (0.37) | DUT | |
| SCHEMBL4336626 | 0.88 | DUT (0.36) | DUT | |
| SCHEMBL12380487 | 0.84 | TDP1 (0.40) | — | |
| SCHEMBL31326668 | 0.79 | HTR1A (0.33) | DUT | |
| SCHEMBL738264 | 0.78 | DUT (0.34) | DUT | |
| SCHEMBL571057 | 0.74 | DUT (0.39) | DUT | |
| SCHEMBL14760492 | 0.73 | DUT (0.34) | DUT | |
| Ammonia Solution, Strong SCHEMBL9187414 | 0.72 | DUT (0.38) | DUT | |
| SCHEMBL334934 | 0.72 | DUT (0.38) | DUT | |
| SCHEMBL11580466 | 0.72 | DUT (0.42) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743440-A1 | IONIZABLE LIPIDS | eTheRNA immunotherapies NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025012376-A1 | IONIZABLE LIPIDS | ETHERNA IMMUNOTHERAPIES NV (BE) | 2025-01-16 | — | — | WO | disclosed |
| US-9744183-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2017-08-29 | — | — | US | disclosed |
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | ONTORII, INC (US) | 2012-12-13 | — | — | US | disclosed |
| EP-2451461-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | Ontorii, Inc (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005761-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS USE THEREOF | ONTORII, INC (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | PNP, RNGTT, TYMP | DUT 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.